Astragaloside IV protects ATDC5 cells from lipopolysaccharide-caused damage through regulating miR-203/MyD88
Context Osteoarthritis (OA) is a degenerative arthrosis sickness. Astragaloside IV (AS-IV) functions by relieving inflammatory damage. Objective We aimed to investigate the mechanism by which AS-IV protects ATD cells from lipopolysaccharide (LPS)-induced damage. Materials and methods ATDC5 cells wer...
Main Authors: | Dexin Li, Guangcheng Li, Yang Chen, Yifei Li, Junfeng Zhang, Dexuan Gao, Linglong Sun, Bo Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2020-01-01
|
Series: | Pharmaceutical Biology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/13880209.2019.1705355 |
Similar Items
-
Astragaloside IV protects diabetic cardiomyopathy against inflammation and apoptosis via regulating TLR4/MyD88/NF-κB signaling pathway
by: Liang Wang, et al.
Published: (2022-01-01) -
Astragaloside IV, as a potential anticancer agent
by: Dongqin Xia, et al.
Published: (2023-02-01) -
Astragaloside IV alleviates lipopolysaccharide‐induced preeclampsia‐like phenotypes via suppressing the inflammatory responses
by: Dilihuma Tuerxun, et al.
Published: (2021-03-01) -
Lipopolysaccharide-induced NF-κB nuclear translocation is primarily dependent on MyD88, but TNFα expression requires TRIF and MyD88
by: Jiro Sakai, et al.
Published: (2017-05-01) -
Pharmacological Effects of Astragaloside IV: A Review
by: Yutong Liang, et al.
Published: (2023-08-01)